

1

Ignite the future - our exciting PAC reliance journey with 48 NRAs

Francesca Mangia, PhD

Associate Regulatory Program Director

F.Hoffmann-La Roche Ltd

Roche Post-Approval Change Reliance Pilot

Major drug substance process change for mAb


Supply critical variation

- EMA reference agency
- Unilateral reliance

Reducing the global approval and implementation timelines for a Major DS Process change

from 2.5 YEARS to 6.5 MONTHS to ensure the continuous supply to patients

- Reduce country specific requirements
- Enhance greater **transparency** to NRAs by sharing EMA assessment report and Q&A





Pilot's Layout & Participation Criteria



One Standard Dossier



EU dossier submitted to all countries



Q&A Document

EU questions and Roche's responses document will be shared with the participating NRAs





EU assessment report will be shared with NRAs

No Country Specific Requirements



No Testing



According to EU, for this type of change, no testing required

One Timeline for All

Ð

Same dossier and Q&A review timelines for all participating NRAs

Roche PAC Reliance Pilot - Participating Countries






84 countries impacted by the change

48 COUNTRIES AGREED to participate in the pilot

57% Acceptance Rate

GREENLAND GREENLAND	1. 2. 3.	Algeria Argentina Australia	16.	Georgia Ghana Guatemala	30.	. New Zealand . Nigeria . Oman	44.	Tunisia Türkiye Ukraine
	4.	Bahrain		Honduras		Panama		United Arab Emirates
	5.	Botswana	19.			Paraguay		Uruguay
- Standard Russia	6	Brunei	20.	Israel		Peru	48.	Zimbabwe
CANADA	(<u>7</u>	Colombia	21.	Jamaica		Qatar		
MAZAMISTAN A	<i>y</i> 8.	Dem. Rep. of Congo	22.	Jordan		Saudi Arabia		
	9.	Costa Rica		Kenya		Serbia		
	10.	Dominican Republic Ecuador		Kuwait		. Sri Lanka . Taiwan		
CHINA STATE	11.			Mexico		. Tanzania		
Sint Maarten, Curacao	12. 13.	Egypt El Salvador		Montenegro Morocco		Thailand		
	14.			Namibia		Trinidad and	Toha	00
 Participates to the pilot Does not participate to the pilot No response on pilot invitation 	NEW ZEAL		20.		42.		TODA	90
Reducing the global approval and implementation timelines								
From 2.5 YEARS to 6.5 MONTHS to ensure continuous supply to patients 4								

Highlights and Timelines



**If approval not granted NRA should share rationale for refusal

Roch

Handling potential Questions & Answers transparently



Continuous

Dialoque

Transparency


Q & A were shared via a Accumulus Synergy Accumulus


- A first-of-its-kind, cloud-based data and information exchange platform supporting regulatory interactions between Life Sciences Organizations and Global Health Authorities
- This tool is a proposal for greater visibility and transparency. All participating NRAs were able to see the questions real-time from other NRAs

Each NRA could choose whether to use the Accumulus Q&A platform or issue Q&As following its standard process via Roche affiliates.

Roche PAC Reliance Pilot Journey










Current Status - Overview of Questions Received





Questions Categories

- Technical
- Clarifying
- Country Specific Document
 - Administrative



Success Factors





Transparency and Dialogue: same variation package as EMA, EMA's Q&As and unredacted assessment report



Support from EMA and WHO, strong advocates for reliance around the globe



Choice of product and supply critical variation: This medicine is used for treating life-threatening diseases and involves a major supply-critical variation with high public health and business impact.



Overall product strategy, especially the impact of the pilot on change implementation, should be continuously and carefully assessed.



Regulatory affiliates of each participating company, which operate in the countries impacted by this variation, play a crucial role as the primary contact with their respective NRAs.

DIA

Conclusion

57% participation rate \rightarrow Strong interest and willingness of many NRAs

across the globe to bring reliance into action for PACs

- 83% of NRAs approved in 6.5 months
- **Transparency** is key in building trust with regulators
- Applying reliance throughout the lifecycle of the product, including PACs,

represents a contribution towards global convergence and harmonization

You want to know more about the Roche PAC Reliance

Pilot? Check out our latest publication on TIRS (LINK)!

ANALYSIS Unleashing the Power of Reliance for Post-Approval Changes: A Journey with 48 National Regulatory Authorities Francesca Mangia¹ · Yameng (Melly) Lin¹ · John Armando² · Kareny Dominguez¹ · Vera Rozhnova¹ Susanne Ausborn¹

Received: 26 April 2024 / Accepted: 18 July 2024 © The Author(s) 2024

Therapeutic Innovation & Regulatory Science https://doi.org/10.1007/s43441-024-00677-8

Post-approval changes (PACs) to marketed products are routinely introduced to continuously enhance the product lifecycle management. However, bringing a chemistry, manufacturing and control (CMC) change through the global health authorities can be a complex and lengthy process taking up to several years, therefore negatively impacting supply continuity. In order to accelerate the review and approval of regulatory submissions and ensure continuous supply to patients, the World Health Organization (WHO) is strongly supporting the implementation of reliance among National Regulatory Authorities (NRAs). While some promising developments have been made with the use of reliance pathways for initial marketing authorizations, reliance is still not widely used for PACs. With the support of the European Medicines Agency (EMA) and WHO, Roche launched a reliance pilot based on EMA approval to file a supply critical variation for a monoclonal antibody. The variation constitutes major changes to the approved manufacturing process. Sameness of the product is ensured by submitting to all participants the same variation package as in the EU. The objectives of the pilot are to ensure continuous supply of this critical medicine by targeting global approval in 6.5 months, to promote regulatory convergence by waiving country specific requirements, and enhance greater transparency by sharing EMA Committee for Medicinal Products for Human Use (CHMP) final assessment report and Q&As to participating NRAs. Globally 48 NRAs have agreed to join the pilot. This article outlines the process of establishing the pilot project, including a planning phase and an engagement phase with the EMA, WHO and the participating NRAs.

Keywords Reliance · Post-Approval Changes · Convergence · Transparency

Introduction

Post-approval changes (PACs) are crucial for the continuous supply of essential medicines, responding to demand surges, change in regulatory requirements, and technologi













Thank you!









